drugset
drugset / Trial / NCT04751539

A Dose-escalation Study of AND017 in Healthy Subjects

NCT04751539 ↗

Phase 1 Completed 78 enrolled Kind Pharmaceuticals LLC
RandomizedSequentialQuadruple-blindTreatment

Summary

This is a phase I, randomized, double-blind, placebo-controlled, dose-escalation study in healthy subjects to evaluate safety, tolerability, PKs and PDs of AND017 following oral single and multiple dose administration.

Timeline

Start
2018-07-16
Primary completion
2019-02-11
Completion
2019-02-11

Drugs

EvaluationDrugModalityDoseRoute
Subject AND017 Unknown 1 mg Oral
Subject AND017 Unknown 4 mg Oral
Subject AND017 Unknown 30 mg Oral
Subject AND017 Unknown 50 mg Oral

Indications

No indication recorded.